Comorbidities and covid-19

Abstract

Better understanding is essential for health system planning

Characteristics of a case-series of COVID-19 reinfection and its trend from 2020 to June 2022 in a general medicine office in Toledo, Spain

“…In line with prior investigations, we discovered that all occurrences of reinfection were mild (45). Strong data currently indicates that those with various health issues are at a higher risk (46). According to other studies, the only symptoms associated with a positive result in reinfections are sore throat and rhinitis (47).…”

The reception of public health messages during the COVID-19 pandemic

“…Such rejections are likely linked to an amelioration of the potential severity of COVID-19, since the word ‘flu’ appears eight times in the context of being similar or worse than COVID-19 in our survey corpus (e.g., ‘We have to get on with life and there has always been flu around’). It is particularly important that this is addressed whilst the long-term risks of COVID-19 are assessed ( Adab et al, 2022 ; Jennings et al, 2022 ; Kao & Frankland, 2022 ). As with the fear appeal messaging, we found respondents were disengaging from this messaging because of its presentation, meaning that disengagement is to some extent avoidable here also.…”

Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi

“…However, the number of COVID-19 preventable deaths are still significant and a greater focus on identifying and protecting those most at risk is increasingly important. It has been widely reported that the elderly and people with comorbidities are at an increased risk of severe COVID-19, [42][43][44][45] and in Malawi, a Malawi Government COVID-19 situation report has shown that the median age for those that succumbed to COVID-19 was 61 years with 64.2% being male. 40 The current vaccination policy for Malawi has expanded the vaccine eligibility age downwards to include those 12 years to 17 years of age for the Pfizer-BioNTech BNT162b2 mRNA vaccine and is also providing booster doses of the same to those that are eligible, but there are not enough vaccine doses to cover the whole eligible but unvaccinated population.…”